NOVERA COMPOUNDS

PE-22-28 10mg

10% off, code: PEPTEN
Purity Guarantee

PE-22-28 10mg

Sign in to view pricing and purchase this product.

Log In Sign Up
Quantity Discount (%) Price
1 - 5 — $55.00
6 - 10 9.09 % $50.00
11 - 20 18.18 % $45.00
21+ 25.45 % $41.00

Why choose Novera Compounds peptides

Research-grade Quality

Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.

Documented and traceable

  • Batch number on every vial

  • Published Certificates of Analysis

  • Purity verified by third-party testing

Handled and shipped with care

Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.

About the product

PE-22-28 is a synthetic peptide derived from a short functional fragment of larger neuroactive peptide structures. It is commonly studied in research settings focused on central nervous system activity and peptide-based signaling. The compound is typically supplied as a purified lyophilized powder in vial format, enabling controlled preparation in laboratory settings.

PE-22-28 has been studied for its potential involvement in neural signaling and behavioral research models. Its defined structure supports consistent use in experimental conditions, particularly in studies examining how short peptide fragments may influence cellular communication and regulatory processes within neurological systems.

PE-22-28 Key Features & Specs

PE-22-28 is prepared for structured laboratory research and is used in controlled experimental settings where peptide consistency and purity are required.

  • Subcategory: Brain, Cognitive & Nootropic Peptides
  • Strength: 10mg
  • CAS: 1801959-12-5
  • Chemical Formula: C₃₅H₅₅N₁₁O₉
  • Molecular Weight: 773.8947 g/mol
  • Peptide Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg

For laboratory research use only.

PE-22-28 Research Uses

PE-22-28 is being researched for its potential role in neurological and behavioral models. Studies often focus on how short peptide fragments may influence cellular signaling within the brain and related systems. It has been examined in experimental environments exploring cognitive function, neural communication, and peptide-mediated activity.

Research involving PE-22-28 also considers its interaction with broader biological systems associated with mood, stress response, and neural regulation. These investigations aim to better understand how peptides may contribute to signaling processes without defining clinical or therapeutic outcomes.

PE-22-28 Insights & Observed Findings

In preclinical and in vitro research, PE-22-28 has been evaluated under controlled conditions to assess its interactions with neural systems. Reported dosage ranges vary by experimental model, with researchers maintaining consistent concentrations to ensure reproducibility.

Observed findings often focus on measurable changes in cellular signaling activity and behavioral responses within controlled study environments. These results are used to support further investigation into peptide-based mechanisms and are not intended to indicate clinical applications.

PE-22-28 Handling & Storage

PE-22-28 should be stored at –20°C in a dry, controlled laboratory environment. The peptide should be protected from light and moisture prior to reconstitution.

Once reconstituted, the solution should be kept under refrigerated conditions and handled using standard laboratory practices. Minimize freeze-thaw cycles during handling to ensure consistency during experimental use.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

  1. Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017;8:643. Published 2017 Sep 12. doi:10.3389/fphar.2017.00643
  2. Mazella J, Pétrault O, Lucas G, et al. Spadin, a Sortilin-Derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biology. 2010;8(4):e1000355. doi:10.1371/journal.pbio.1000355
  3. Djillani A, Mazella J, Heurteaux C, Borsotto M. Role of TREK-1 in health and disease, Focus on the central nervous system. Frontiers in Pharmacology. 2019;10:379. doi:10.3389/fphar.2019.00379
  4. Borsotto M, Veyssiere J, Moha Ou Maati H, Devader C, Mazella J, Heurteaux C. Targeting two-pore domain K(+) channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept. Br J Pharmacol. 2015;172(3):771-784. doi:10.1111/bph.12953